Media Articles Related to Gammaplex (Human Immunoglobulin G)
Minipool technology to prepare immunoglobulins to treat primary immunodeficiency and fight viral infections, such as Ebola, in developing countries
Source: Tropical Diseases News From Medical News Today [2015.02.27]
A study publishing in PLOS Neglected Tropical Diseases describes a new, pragmatic, method for the production of immunoglobulin G (IgG) from human plasma in developing countries.
Human Immunodeficiency Virus (HIV)
Source: MedicineNet amprenavir Specialty [2014.03.03]
Title: Human Immunodeficiency Virus (HIV)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 3/3/2014 7:32:12 PM
Acquired Immunodeficiency Syndrome
Source: MedicineNet Human Immunodeficiency Virus (HIV, AIDS) Specialty [2013.05.21]
Title: Acquired Immunodeficiency Syndrome
Category: Diseases and Conditions
Created: 2/3/2010 12:00:00 AM
Last Editorial Review: 5/21/2013 12:00:00 AM
Human Immunodeficiency Virus
Source: MedicineNet Interstitial Pneumonia Specialty [2006.05.22]
Title: Human Immunodeficiency Virus
Category: Diseases and Conditions
Last Editorial Review: 5/22/2006
'Cell-tweaking' technique offers treatment hope for 'bubble boy disease' SCID
Source: Stem Cell Research News From Medical News Today [2015.03.13]
For the first time, researchers have generated missing immune cells from gene-edited stem cells made from cells of a patient with X-linked severe combined immunodeficiency disease.
Published Studies Related to Gammaplex (Human Immunoglobulin G)
Intranasal vaccination with a replication-deficient influenza virus induces
heterosubtypic neutralising mucosal IgA antibodies in humans. 
We investigated the cross-neutralising potential of serum and nasal wash samples
from volunteers who were intranasally immunised once with a monovalent
replication-deficient delNS1-H1N1 influenza virus vaccine
(7.7log10TCID50/volunteer). Eight out of twelve (8/12) vaccinees responded to
vaccination with a significant increase of antibody levels in serum IgG ELISA,
mucosal IgA ELISA, MNA or HAI...
Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following
vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle
The exploratory immunogenicity objective of this analysis was to characterize the
titer of vaccine human papillomavirus (HPV)-type immunoglobulins in both
peripartum maternal blood and the cord blood of infants born to women who
received blinded therapy.
Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans. [2011.02]
Attenuated live oral typhoid vaccine candidate CVD 909 constitutively expresses Salmonella Typhi capsular polysaccharide antigen (Vi). A randomized, double-blind, heterologous prime-boost clinical study was conducted to determine whether immunity to licensed parenteral Vi vaccine could be enhanced by priming with CVD 909...
Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral
boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S.
Typhi-specific IgA and IgG B memory cells in humans. 
Attenuated live oral typhoid vaccine candidate CVD 909 constitutively expresses
Salmonella Typhi capsular polysaccharide antigen (Vi). A randomized,
double-blind, heterologous prime-boost clinical study was conducted to determine
whether immunity to licensed parenteral Vi vaccine could be enhanced by priming
with CVD 909...
Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans. [2010.12]
Merck V710 is a novel vaccine containing the conserved Staphylococcus aureus iron surface determinant B shown to be protective in animal models. A phase I, multicenter, double-blind study of the dose range was conducted to assess the immunogenicity and safety of an adjuvanted liquid formulation of V710...
Clinical Trials Related to Gammaplex (Human Immunoglobulin G)
A Study to Find How Safe and Effective GAMMAPLEX« is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP) [Recruiting]
The primary objective is to determine if BPL's GAMMAPLEX raises the platelet count of
subjects with chronic ITP to a threshold of 50 x 109/L, similar to that of a historical
control. The secondary objectives are: 1) to determine the safety of GAMMAPLEX at the
dosage used in this study. 2) to determine if GAMMAPLEX maintains platelet counts of │ 50 x
109/L in subjects with chronic ITP for a period of time similar to that of a historical
Trial of the Efficacy of Intravenous Immunoglobulin for Treating Women With Unexplained Secondary Recurrent Miscarriage [Recruiting]
The investigators want to test whether infusions of intravenous immunoglobulin - a blood
product known to modify immune responses - in early pregnancy will increase the chance of a
subsequent live birth in women with three or more miscarriages after a birth and a total of
at least four miscarriages. This will be done in a trial where 82 patients will be randomly
allocated to infusions with intravenous immunoglobulin or placebo during pregnancy.
Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency [Recruiting]
The purpose of this open-label study is to evaluate the pharmacokinetics, safety, and
tolerability of subcutaneously (SC; under the skin) administered GAMUNEX«-C compared to
intravenously (IV; through the vein) administered GAMUNEX«-C in subjects 2-16 years of age
with Primary Immunodeficiency.
A Study to Find Out How Safe and Effective Gammaplex« is in Young People With Primary Immunodeficiency [Recruiting]
The main objective is to determine the efficacy of Gammaplex by measuring the number of
serious acute bacterial infections during treatment with Gammaplex over a 12 month period.
The secondary objectives are to assess the safety and tolerability of Gammaplex and to
compare the data collected from adult subjects with PID from the GMX01 study
Intravenous Immunoglobulins in Severe and Refractory Solar Urticaria [Recruiting]
Solar urticaria is a rare but debilitating disease that can severely impact the quality of
life, restricting outdoor activities. Treatment, based on sun protection and anti-histaminic
drugs, is efficacious in 2 patients out of 3. In refractory patients, photodesensitization
or immunosuppressive treatments such as cyclosporin A can be proposed. As in idiopathic
urticaria, intravenous immunoglobulins (IVIG)have been shown, in a retrospective study of 7
patients, to dramatically improve 71% of patients. In an open-label prospective multicenter
study, we aim to demonstrate the efficacy of a single IVIG administration (2g/kg) in 10
patients affected with severe and refractory solar urticaria.
Reports of Suspected Gammaplex (Human Immunoglobulin G) Side Effects
International Normalised Ratio Decreased (4),
Pulmonary Embolism (3),
Drug Interaction (2),
Chest Pain (2),
Abdominal Pain (1),
Viith Nerve Paralysis (1), more >>